Forum for Science, Industry and Business

CeNeS announces additional clinical data supporting the potential of M6G for the treatment of post-operative pain

CeNeS Pharmaceuticals notes the recent publication of additional clinical data on its lead product morphine-6-glucuronide (M6G) by an academic group at King’s College, London. The data, which was published in the international journal ‘Anesthesiology’ (1), provides further support for the potential of M6G as a treatment for post-operative pain, focusing on its potential for administration under patient-controlled analgesia (PCA). Part of this data has been presented previously at the 4th International Symposium for Nociceptive/Neuropathic Pain, King’s College Hospital.

The study, which was a randomised, double-blind study comparing the analgesic efficacy of M6G and morphine administered by initial bolus followed by PCA in 100 patients undergoing major joint replacement. Under the PCA system, patients administer their own pain relief as and when it is needed.

The key findings of the study are:

• M6G has analgesic potency similar to that of morphine. The authors speculate that the less effective pain control observed at early time points in this study in patients on M6G could be due to the need for a large loading dose or the product’s slower onset of action.
• There were clear differences between the M6G and morphine groups in terms of respiratory depression rates. The proportion of subjects with respiratory depression was markedly higher in the morphine group (27%) compared with the M6G group (6%).
• There was significantly less sedation in the M6G group in the immediate post-operative period as well as at the end of the 24 hour study period
• 24 hours post-surgery, when the nausea rate was at its highest, 41% of patients receiving morphine experienced nausea compared with 21% of those receiving M6G. However, this difference did not reach the level of statistical significance.
• The group concludes “it (M6G) has a unique pharmacodynamic profile with a better therapeutic window than morphine. Its simple, clean pharmacokinetic characteristics make it an attractive agent for further investigation…”

Commenting on the publication, Neil Clark, Chief Executive Officer of CeNeS said, “This new data adds further support to our reported clinical trial results and our belief in the potential of M6G as a new drug for the treatment of post-operative pain with significant advantages over morphine and other opiates. We believe that the less effective pain control observed with M6G at early time points in this study is due to the low loading doses used. Our first Phase III trial clearly showed that a higher loading dose of 30mg provides effective analgesia. This higher loading dose regime will be used in our second Phase III trial, which is expected to start in the next few months. If we are successful in demonstrating the efficacy and superior side effect profile of M6G compared to morphine in this large Phase III trial, which will involve approximately 440 patients, then we will have made a significant step towards the approval of the product in Europe.”

Rowan Minnion | alfa
Further information:
http://www.cenes.com

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...